Early specific diagnosis and effective treatment of hepatocellular carcinoma (HCC) are
crucial. Expression of membrane-associated heparan sulfate proteoglycan glypican-3 (GPC …

Liver cancer is the second leading cause of cancer‐related deaths, and hepatocellular
carcinoma (HCC) is the most common type. Therefore, molecular targets are urgently …

Background Glypican 2 (GPC2), a member of glypican (GPC) family genes, produces
proteoglycan with a glycosylphosphatidylinositol anchor. It has shown its ascending …

Esophageal squamous cell carcinoma (ESCC) has a poor prognosis despite the
development of multimodal therapy. Expression of glypican-1 (GPC1) has been reported to …

Glypican 3 (GPC3), a membrane-bound heparin sulfate proteoglycan, is mutated in Simpson-
Golabi-Behmel syndrome, characterized by tissue overgrowth and an increased risk of …

Cancer care is being revolutionized by immunotherapies such as immune checkpoint
inhibitors, engineered T cell transfer, and cell vaccines. The bispecific T cell–redirecting …

Embryonal tumors, such as neuroblastoma, medulloblastoma and Wilms' tumor, have their
peak incidence in the first 4 years of life. These neoplasias exhibit genetic and clinical …

Expression profiling of hepatocellular carcinoma has demonstrated that glypican 3 (GPC3),
a heparan sulfate proteoglycan anchored to the membrane, is expressed at a markedly …

Summary Glypican 2 (GPC2) is a MYCN-regulated, differentially expressed cell-surface
oncoprotein and target for immune-based therapies in neuroblastoma. Here, we build on …

Abstract Glypican-3 (GPC3) is a heparan sulfate proteoglycan that plays an important role in
cell growth and differentiation. GPC3 function is tissue dependent. In some tissues, GPC3 …